Literature DB >> 15449064

Standards of medical treatment and nutrition in Crohn's disease.

Britta Siegmund1, Martin Zeitz.   

Abstract

Crohn's disease is a condition of chronic inflammation potentially involving any location of the alimentary tract from mouth to anus but with a propensity for the distal small bowel and proximal large bowel. Frequent complications include stricture and fistula. Numerous extra-intestinal manifestations may also be present. The aetiology of Crohn's disease is incompletely understood, and therapy, although generally effective in alleviating the symptoms, is not curative. Due to the heterogeneity of the disease a major need for the therapeutic approach is the ability to define subgroups with distinct characteristics. However, with regard to the heterogeneity of demographic, anatomic and disease behaviour characteristics, distillation of the numerous possible phenotypes in simple categories is a formidable task. In the present review the focus will be on clinically relevant situations providing therapeutic algorithms according to international guidelines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15449064     DOI: 10.1007/s00423-004-0498-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  43 in total

1.  Enteral nutrition in children with Crohn's disease.

Authors:  R B Heuschkel
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-11       Impact factor: 2.839

2.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

3.  Mesalamine and relapse prevention in Crohn's disease.

Authors:  M Cottone; C Cammà
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

4.  Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.

Authors:  K Fellermann; M Steffen; J Stein; A Raedler; J Hämling; D Ludwig; K Loeschke; E F Stange
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

5.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

Authors:  B Landi; T N Anh; A Cortot; J C Soule; E Rene; J P Gendre; P Bories; A See; E H Metman; C Florent
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

6.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  [Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study].

Authors:  M U Schneider; G Laudage; I Guggenmoos-Holzmann; J F Riemann
Journal:  Dtsch Med Wochenschr       Date:  1985-11-08       Impact factor: 0.628

9.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

10.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

View more
  1 in total

Review 1.  Bacterial translocation - impact on the adipocyte compartment.

Authors:  Tassilo Kruis; Arvind Batra; Britta Siegmund
Journal:  Front Immunol       Date:  2014-01-06       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.